December 1, 2020, is #GivingTuesday! Will you help #EndALS by fundraising or making a direct donation to ALS TDI? Your support fuels our research!
Quick Info
Status
Ongoing, But Not Recruiting
Estimated Enrollment
90
Phase
1
Treatment Type
Drug: BIIB078
Trial Type
Randomized, Sequential assignment, quadruple masking
Sponsor
Primary Investigator
Medical Director, Biogen
Contact Information
Locations
Canada, Alberta
Research Site, Calgary, AB, T2N 1N4, Canada
Canada, Ontario
Research Site, Toronto, ON, M4N 3M5, Canada
Canada, Quebec
Research Site, Montreal, QC, H3A 2B4, Canada
Netherlands, Other
Research Site, Utrecht, 3508 GA, Netherlands
Switzerland, Other
Research Site, St. Gallen, 9007, Switzerland
United Kingdom, Other
Research Site, London, SE5 9RS, United Kingdom
Research Site, London, NW1 2PG, United Kingdom
Research Site, Sheffield, S10 2HQ, United Kingdom
United States, California
Research Site, La Jolla, CA, 92037-0886, United States
Research Site, Los Angeles, CA, 90048, United States
Research Site, Palo Alto, CA, 94303, United States
United States, Florida
Research Site, Jacksonville, FL, 32224, United States
Research Site, Miami, FL, 33136, United States
United States, Georgia
Research Site, Atlanta, GA, 30322, United States
United States, Maryland
Research Site, Baltimore, MD, 21287, United States
United States, Massachusetts
Research Site, Boston, MA, 02114, United States
United States, Missouri
Research Site, Saint Louis, MO, 63110, United States
United States, Nebraska
Research Site, Lincoln, NE, 68506-2960, United States
United States, New York
Research Site, New York, NY, 10032, United States
United States, Tennessee
Research Site, Knoxville, TN, 37920, United States
Enrollment Criteria
Breathing Ability
Percent lung function (FVC) or (SVC)
(SVC) ≥ 50%
Months Since Onset
Number of months since first symptoms of ALS.
not specified
Non-Invasive Ventilation (NIV)
Can PALS use a BiPAP in the trial?
no
Diaphragm Pacer (DPS)
Can PALS use a DPS in the trial?
no
Edaravone Usage
Can a PALS use edaravone (Radicut/Radicava) while enrolled in the trial?
Yes
Update Notes
No significant updates
5/5/2020
No significant updates.
3/14/2020
No significant updates
12/2/2019
Locations added
10/25/2019
Updated anticipated trial completion date
10/4/2019
No significant updates
9/24/2019
Added New Site Location
9/12/2019
No significant updates
6/5/2019
Recruitment status updated
5/20/2019
Locations updated
3/20/2019
Locations updated
3/20/2019
Locations updated
3/4/2019
Locations and recruitment status updated
11/15/2018
Locations updated
10/26/2018
Recruitment status updated
9/17/2018
Trial added
8/20/2018

Other Information

Purpose
The primary objective of this study is to evaluate the safety and tolerability of BIIB078 in adults with C9ORF72-Amyotrophic Lateral Sclerosis (ALS). The secondary objectives of this study are to evaluate the pharmacokinetic profile of BIIB078 and to evaluate the effects of BIIB078 on clinical function. As the first-in-human study, the study enrolls a small number of participants in each cohort. Every participant in a cohort is treated with the same dose or placebo. The study is designed to evaluate and confirm the safety of each dose before enrolling and exposing new participants to a higher dose in the next cohort. Therefore, proceeding from cohort to cohort, the recruitment status of "Active, not recruiting" may change. Please contact clinicaltrials@biogen.com for further information.
Eligibility
Key Inclusion Criteria:
- Ability of the participant to understand the purpose and risks of the study, to provide signed and dated informed consent, and to authorize the use of confidential health information in accordance with national and local participant privacy regulations; or, in the event of the participant's physical incapacity to sign, to confirm that understanding and consent orally to a legally authorized representative (LAR) for the express purpose of having said informed consent and authorization signed on his/her behalf.
- All participants of childbearing potential must agree to practice highly effective contraception during the study and be willing and able to continue contraception for 5 months after their last dose of study treatment.
- Must meet the possible, laboratory-supported probable, probable, or definite criteria for diagnosing ALS according to the World Federation of Neurology El Escorial criteria and have documentation of a clinical genetic test demonstrating the presence of a pathogenic mutation in C9ORF72.
- Slow vital capacity (SVC) ≥ 50% of predicted value as adjusted for sex, age, and height (from the sitting position).
- Participants taking concomitant riluzole at study entry must be on a stable dose for ≥ 30 days prior to the first dose of study treatment (Day 1).
- Participants taking concomitant edaravone at study entry must be on a stable dose for ≥ 60 days prior to the first dose of study treatment (Day 1).
- ALS Cognitive Behavioral Screen (ALS-CBS) score ≥ 11 for the cognitive portion; ≥ 33 for the behavioral portion.
- Medically able to undergo the study procedures, and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.
- Screening values of coagulation parameters including platelet count, international normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (APTT) should be within normal ranges.
- Has an informant/caregiver who, in the Investigator's judgment, has frequent and sufficient contact with the participant as to be able to provide accurate information about the participant's cognitive and functional abilities at Screening.
Key Exclusion Criteria:
- History of drug abuse or alcoholism ≤ 6 months of Screening that would limit participation in the study, as determined by the Investigator.
- Tracheostomy.
- Prescreening ALSFRS-R slope less than 0.4 points/month, where prescreening ALSFRS-R slope is defined as follows: (48 - ALSFRS-R score at Screening) / (months from date of symptom onset to date of Screening).
- History of or positive test result at Screening for human immunodeficiency virus. .
- History of, or positive test result at Screening for, hepatitis C virus antibody.
- Treatment with another investigational drug or biological agent within 1 month of Screening or 5 half-lives of study agent, whichever is longer.
- Treatment with an antiplatelet or anticoagulant therapy that cannot safely be interrupted for lumbar puncture (LP) according to local standard of care and/or institutional guidelines, in the opinion of the Investigator or Prescriber.
- Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system during the study period.
- Female participants who are pregnant or currently breastfeeding.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Details
Collaborator(s)
  • Biogen
Trial Protocol as Published on Clinicaltrials.gov
NCT03626012 (First Published: 8/7/2018)